Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Company research

INSTINCT BIO TECHNICAL CO HOLDINGS INC.

CIK 2072188Updated Oct 6, 2026

Name history
Relativity Holdings Inc. · through Jul 23, 2026

BIOT price & chart

Provider market data

Loading TradingView…

NASDAQ:BIOT on TradingView ↗

TradingView · Data may be delayed

About the company

INC. INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) is a diversified healthcare and biotechnology company focused on developing and expanding businesses across beauty, wellness, regenerative medicine and related healthcare sectors. Through its operations and strategic partnerships, BIOT seeks to build an integrated platform connecting innovative healthcare technologies, products and services with growth opportunities across Asia and other international markets. For more information, please visit https://instinct-biot.com/

6-K · 2026-10-01 · 0001104659-26-112508

Company description from the cited filing.

In the news

No coverage from other publishers is available.

Recent filings

  1. 6-K filing

    6-K · 2026-10-01 · 0001104659-26-112508

  2. 6-K filing

    6-K · 2026-09-15 · 0001104659-26-107729

  3. 6-K filing

    6-K · 2026-09-08 · 0001104659-26-105598

  4. 6-K filing

    6-K · 2026-08-10 · 0001104659-26-093174

  5. 6-K filing

    6-K · 2026-07-31 · 0001104659-26-089037

Show 5 more recent filings
  1. 6-K filing

    6-K · 2026-07-30 · 0001104659-26-088487

  2. 20-F filing

    20-F · 2026-07-29 · 0001104659-26-087649

  3. 6-K filing

    6-K · 2026-07-28 · 0001104659-26-087358

  4. CERT filing

    CERT · 2026-07-23 · 0001354457-26-000726

  5. 8-A12B filing

    8-A12B · 2026-07-23 · 0001104659-26-086161

Filing attachments

tm2626707d1_ex99-1.htm · 6-K · 2026-10-01

Exhibit 99.1 BIOT Named Authorized Representative for IN01 Cancer Immunotherapy in Japan and China Non-exclusive appointment by CelSiege Biosciences extends BIOT's business development activities into clinical-stage oncology NEW YORK and TOKYO, September 30, 2026 - INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) ("BIOT" or the "Company") today announced that CelSiege Biosciences Inc. ("CelSiege") has appointed BIOT, on a non-exclusive basis, as its authorized introduction and bu…

6-K · 2026-10-01 · 0001104659-26-112508

Read attachment ↗
tm2625442d1_ex99-1.htm · 6-K · 2026-09-15

Exhibit 99.1 Instinct Bio Receives Nasdaq Notifications Regarding Minimum Bid Requirement and Minimum Market Value of Listed Securities and Publicly Held Shares NEW YORK and TOKYO, September 15, 2026 - Instinct Bio Technical Company Holdings Inc. (Nasdaq Symbols: BIOT, BIOTW) (“Instinct Bio” or the “Company”) today announced that on September 9, 2026 and September 10, 2026 it received notifications from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), as describ…

6-K · 2026-09-15 · 0001104659-26-107729

Read attachment ↗
tm2624858d1_ex99-1.htm · 6-K · 2026-09-08

Exhibit 99.1 INSTINCT BIO Provides Operational Update on Indonesia Growth Platform and Product Development Initiatives Follow-up to the Company’s July 29, July 30 and August 10, 2026 announcements NEW YORK and TOKYO, September 4, 2026 (GLOBE NEWSWIRE) - INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) (“Instinct Bio” or the “Company”) today provided an operational update on the initiatives previously announced on July 29, July 30 and August 10, 2026, relating to its GENRÊVER CLINIC…

6-K · 2026-09-08 · 0001104659-26-105598

Read attachment ↗
tm2622710d1_ex99-1.htm · 6-K · 2026-08-10

Exhibit 99.1 Instinct Bio Announces Strategic Collaboration with PT PARVA CANDELA to Develop Cosmetics Business in Indonesia NEW YORK, NY and TOKYO, JAPAN - August 10, 2026 - INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) (“Instinct Bio” or the “Company”) today announced a cooperation agreement with PT PARVA CANDELA ("PARVA"), an Indonesian cosmetics manufacturer and distributor, to jointly develop Indonesia’s cosmetics and personal care market under a "Made in Indonesia, Powered …

6-K · 2026-08-10 · 0001104659-26-093174

Read attachment ↗
tm2621810d1_ex99-1.htm · 6-K · 2026-07-31

Exhibit 99.1 Instinct Bio Announces Strategic Collaboration with INVITRX to Expand GENRÊVER into U.S. and Advance Indonesia Regenerative Medicine Initiatives Collaboration combines Japanese product innovation, U.S. GMP manufacturing capabilities and regenerative medicine expertise to support the next phase of Instinct Bio's international growth NEW YORK, NY and TOKYO, JAPAN - July 30, 2026 - INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) ("Instinct Bio" or the "Company") today an…

6-K · 2026-07-31 · 0001104659-26-089037

Read attachment ↗
tm2621671d1_ex99-1.htm · 6-K · 2026-07-30

Exhibit 99.1 BIOT to Launch Indonesia’s First Subscription-Model Beauty Clinics Under Its Own Japanese Brand “GENRÊVER CLINIC” - Building a Recurring-Revenue Platform in One of Asia’s Fastest-Growing Aesthetics Markets First wave of five directly operated clinics across Indonesia’s five major metropolitan areas with an initial investment of approximately US$1 million; standardized, machine-led clinic format designed for disciplined, self-funded expansion; positioned as a strategic gateway to t…

6-K · 2026-07-30 · 0001104659-26-088487

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.